RT Journal Article
SR Electronic
T1 Association between Use of Qingfei Paidu Tang and Mortality in Hospitalized Patients with COVID-19: A national retrospective registry study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.23.20248444
DO 10.1101/2020.12.23.20248444
A1 Zhang, Lihua
A1 Zheng, Xin
A1 Bai, Xueke
A1 Wang, Qing
A1 Chen, Bowang
A1 Wang, Haibo
A1 Lu, Jiapeng
A1 Hu, Shuang
A1 Zhang, Xiaoyan
A1 Zhang, Haibo
A1 Liu, Jiamin
A1 Shi, Ying
A1 Zhou, Zhiye
A1 Gan, Lanxia
A1 Li, Xi
A1 Li, Jing
YR 2020
UL http://medrxiv.org/content/early/2020/12/26/2020.12.23.20248444.abstract
AB Background Qingfei Paidu Tang (QPT), a formula of traditional Chinese medicine, which was suggested to be able to ease symptoms in patients with Coronavirus Disease 2019 (COVID-19), has been recommended by clinical guidelines and widely used to treat COVID-19 in China. However, whether it decreases mortality remains unknown.Purpose We aimed to explore the association between QPT use and in-hospital mortality among patients hospitalized for COVID-19.Study design A retrospective study based on a real-world database was conducted.Methods We identified patients consecutively hospitalized with COVID-19 in 15 hospitals from a national retrospective registry in China, from January through May 2020. Data on patients’ characteristics, treatments, and outcomes were extracted from the electronic medical records. The association of QPT use with mortality was evaluated using Cox proportional hazards models based on propensity score analysis.Results Of the 8939 patients included, 28.7% received QPT. The crude mortality was 1.2% (95% confidence interval [CI] 0.8% to 1.7%) among the patients receiving QPT and 4.8% (95% CI 4.3% to 5.3%) among those not receiving QPT. After adjustment for patient characteristics and concomitant treatments, QPT use was associated with a relative reduction of 50% in in-hospital mortality (hazard ratio, 0.50; 95% CI, 0.37 to 0.66 P <0.001). This association was consistent across subgroups by sex and age. Meanwhile, the incidence of acute liver injury (8.9% [95% CI, 7.8% to 10.1%]vs. 9.9% [95% CI, 9.2% to 10.7%]; odds ratio, 0.96 [95% CI, 0.81% to 1.14%], P =0.658) and acute kidney injury (1.6% [95% CI, 1.2% to 2.2%] vs. 3.0% [95% CI, 2.6% to 3.5%]; odds ratio, 0.85 [95% CI, 0.62 to 1.17], P =0.318) was comparable between patients receiving QPT and those not receiving QPT. The major study limitations included that the study was an observational study based on real-world data rather than a randomized control trial, and the quality of data could be affected by the accuracy and completeness of medical records.Conclusions QPT was associated with a substantially lower risk of in-hospital mortality, without extra risk of acute liver injury or acute kidney injury among patients hospitalized with COVID-19.Competing Interest StatementDr Li reported receiving research grants, through Fuwai Hospital, from the People's Republic of China for work to improve the management of hypertension and blood lipids and to improve care quality and patient outcomes of cardiovascular disease; receiving research agreements, through the National Center for Cardiovascular Diseases and Fuwai Hospital, from Amgen for a multicenter clinical trial assessing the efficacy and safety of omecamtiv mecarbil and for dyslipidemic patient registration; receiving a research agreement, through Fuwai Hospital, from Sanofi for a multicenter clinical trial on the effects of sotagliflozin; receiving a research agreement, through Fuwai Hospital, with the University of Oxford for a multicenter clinical trial of empagliflozin; receiving a research agreement, through the National Center for Cardiovascular Diseases, from AstraZeneca for clinical research methods training outside the submitted work; and receiving a research agreement, through the National Center for Cardiovascular Diseases, from Lilly for physician training outside the submitted work. No other disclosures were reported.Funding StatementThis project was supported by the Chinese Academy of Medical Sciences Innovation Fund for Medical Science (2020-I2M-Cov19-003) and the National Natural Science Foundation of China under Grants (No. U1611261). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee at the First Affiliated Hospital, Sun Yat-sen University approved the current analysis. Informed consent of individual patients was waivedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data sharing needs to be approved by national registry, which is under the supervision of National Health commission. However, on site data audit is allowed under current regulation.QPTQingfei Paidu TangCOVID-19Coronavirus Disease 2019IQRinterquartile rangeSMDstandard mean differenceIPTWinverse probability treatment weightingHRhazard ratiosORodds ratiosCIconfidence interval